INGELHEIM, Germany & COPENHAGEN, Denmark - Sunday, October 9th 2016 [ME NewsWire]

    Significant increase in progression-free survival was observed with nintedanib; this did not translate into an overall survival benefit
    Learnings from this study will help refine oncology research strategy for the future benefit of patients

(BUSINESS WIRE)-- Boehringer Ingelheim today announced the LUME-Colon 1 trial, investigating nintedanib* plus best supportive care (BSC) versus BSC alone, met one of the co-primary endpoints of progression-free survival (PFS) in pre-treated patients with metastatic colorectal cancer (mCRC), who no longer responded to, or tolerated, other available treatments. While nintedanib showed clear anti-tumour activity and significantly reduced the risk of disease progression by 42% versus BSC, this did not translate into an overall survival (OS) benefit, the second co-primary endpoint. The data showed that the a ... Read more »

Dubai, United Arab Emirates - Sunday, October 9th 2016 [ME NewsWire]

Wilo Middle East FZE , the leading pump manufacturer Headquartered in Germany, partook in the 18th Water, Energy, Technology, and Environment Exhibition (WETEX) held in Dubai during 4–6 October 2016 under the theme ‘At the Forefront of Sustainability.’ This marks the fourth consecutive participation of Wilo in this exhibition which is the largest platform gathering investors and decision makers from energy, water and environment sectors.

The participation of Wilo Middle East FZE, the Middle Eastern regional platform of Wilo SE, covered all applications displaying different types of pumps used in heating, air-conditioning and cooling, water supply, drainage and sewage and industrial processes.

“With its fourth participation in WETEX since 2013; Wilo Middle East FZE renews its confidence in this prestigious event,” commented Bishara Khalil, Managing Director of Wi ... Read more »

INGELHEIM, Germany & COPENHAGEN, Denmark - Sunday, October 9th 2016 [ME NewsWire]

    A reduction in the risk of death was observed in the LUX-Lung 7 trial for patients treated with afatinib versus gefitinib, without reaching significance
    Updated results reaffirm that afatinib significantly improved progression-free survival and time to treatment failure, as well as increased overall response rate compared to gefitinib without compromising overall health-related quality of life, safety and tolerability

(BUSINESS WIRE)-- Boehringer Ingelheim today announced results from the LUX-Lung 7 trial that directly compared the efficacy and safety of second-generation EGFR-directed therapy afatinib* (Giotrif®) and first-generation gefitinib (Iressa®), in the first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). The trial investigated overall survival (OS) as a primary endpoint ... Read more »